retatrutide phase 2 study results just delivered one of the largest weight-loss signals we've ever seen in a medication trial. In a study: • Up to 24.2% mean weight loss at 48 weeks Retatrutide—A Game Changer in Obesity

It gets there by combining appetite control from GLP-1, an insulin boost from GIP, and energy burning from glucagon

While GLP-1 medications may reduce appetite and caloric intake, they can also lead to a reduction in overall protein consumption, which is vital for muscle maintenance and growth

Start by choosing a time that fits your routine and adjust based on your body's feedback

Awareness of these diverse techniques allows patients to make educated choices regarding their care and work towards the best possible outcome for their weight and appearance goals

Lets tackle the how

GLP-1-based therapies led to favorable changes in body composition, with significant reductions in VAT and FBM, particularly during the first six months